Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

The National Triglyceride Alliance (NTA) is proud to announce its official launch, marking a pivotal step in advancing ...

Ionis has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen.

In return, Ionis will receive an undisclosed upfront payment from Sobi. It is also eligible to receive milestone payments and a tiered royalty on the drug's future sales.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty ...

Ionis Pharmaceuticals, Inc. today announced that it has entered into a license agreement under which Sobi® receives exclusive rights in countries outside the U.S., Canada and China to commercialize ...

Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

JPMorgan lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $45 from $47 and keeps a Neutral rating on the shares. The firm ...